Teva Reports That Court Will Hear Its Appeal On COPAXONE Patent

Teva Pharmaceutical Industries announced that the U.S. Supreme Court has granted its COPAXONE certiorari petition. The Court will hear the company’s appeal of a decision regarding the claim invalidation of the U.S. “808 Patent” for the drug.
Source: Pharmaceutical Online News - Category: Pharmaceuticals Source Type: news